- Meeting abstract
- Open Access
Stability monitoring of some acetylcholinesterase reactivating drugs
© Ram et al; licensee BioMed Central Ltd. 2011
- Published: 5 September 2011
- Nerve Agent
- Organophosphorous Compound
- Octadecyl Silica
- Theoretical Plate Number
- Acidic Milieu
Widespread use of organophosphorous compounds (OPs) in agriculture and as nerve agents as well as a lack of clinically effective antidotes initiated the synthesis of new pyridinium bis-aldoximes (K-compounds) with high potency in reactivating acetylcholinesterase irreversibly inhibited by OPs [1, 2]. We aimed to optimize an HPLC method sensitive enough to determine K-compounds from different biological matrices (blood, brain and cerebrospinal fluid) [3, 4].
Samples of biological origin needed proper clean-up. An RP-HPLC method using either UV and amperometric detector was used following separation on a Zorbax Rx-C18 octadecyl silica column with a mobile phase of phosphate buffer with 20% acetonitrile (pH 3.7). 1-Octane sulphonic acid sodium salt (OSA) was used as ion-pairing agent. Calculation of theoretical plate number, asymmetry of peaks, limit of quantitation (LOQ), lower limit of detection (LLOD) and determination of pH, temperature and OSA concentration dependence was done.
Elution characteristics of bis-pyridinium mono-aldoximes were depending on the OSA concentration, however, to a lesser extent than the bis-pyridinium bis-aldoximes. A double bond in the alkyl chain decreased the dependence from the ion-pairing agent concentration only to a minor extent. When the samples were kept at a pH under 1.5 a peak of degradation product was generated. The time course of degradation in an acidic milieu was calculated.
Appropriate clean-up, optimal concentration of the ion-pairing agent and a well-selected mode of detection are the key factors for optimal determinations. We point out decomposition of pyridinium aldoximes at acidic pH.
- Kuča K, Cabal J: In vitro reactivation of tabun-inhibited acetylcholinesterase using new oximes – K027, K005, K033 and K048. Cent Eur J Public Health. 2004, 12 (Suppl): S59-S61.PubMedGoogle Scholar
- Petroianu GA, Nurulain SM, Nagelkerke N, Shafiullah M, Kassa J, Kuča K: Five oximes (K-27, K-48, obidoxime, HI-6 and trimedoxime) in comparison with pralidoxime: survival in rats exposed to methyl-paraoxon. J Appl Toxicol. 2007, 27: 453-457. 10.1002/jat.1224.View ArticlePubMedGoogle Scholar
- Kalász H, Fürész J, Tekes K: Monitoring the pharmacokinetics of pyridinium aldoximes in the body. Mini Rev Med Chem. 2009, 9: 448-462. 10.2174/138955709787847921.View ArticleGoogle Scholar
- Szegi P, Kalász H, Laufer R, Kuča K, Tekes K: Pyridinium aldoxime analysis by HPLC: the method for studies on pharmacokinetics and stability. Anal Bioanal Chem. 2010, 397: 579-586. 10.1007/s00216-010-3635-6.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.